Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, October 14, 2026

Back to today

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SOLS $9.7B
Yet Another Value Podcast 86 clicks

From X

@StableBread

Fajasy on X

Archimedes Tech SPAC Partners II $ATII, the SPAC taking atomic-scale coatings maker Forge Nano public, amended the $100M lead commitment in its PIPE on October 13, three days before the October 16 merger vote. Alyeska, the Chicago hedge fund behind that $100M, will now take 7,031,175 of its 10M shares as pre-funded warrants, up from the 3M planned as of September 24. Those warrants cost $0.0001/share to exercise and never expire, but they don't vote until exercised, and Alyeska can cap its ownership at 4.9%, 9.9%, or 19.9% of the shares. ATII and its sponsor, with the consent of BTIG (the bank that ran ATII's IPO), also waived the transfer restrictions on the 3M founder shares the sponsor hands Alyeska for free at close. Counting the founder share transfer, Alyeska's effective cost is $7.69/share, and the S-4 (the merger filing) says so directly. So the $100M still lands at close, but the fund providing it got more flexible terms the day before ATII holders had to decide whether to redeem.
@BrokenMoats 3 clicks

Broken Moats on X

Hottest trade in the past month.....retail stocks Seems odd with rates and oil and diesel moves over the same time frame. And these are not bounces from being oversold these are double digit moves in most cases to new highs while dpz struggled on their print this week, stocks like DKS collapsed around the time this trade started. Bifurcation in retail in recent weeks that seems to be favoring low quality. Something to watch for a reversal soon $KSS $FIGS $URBN $SHOP

Investor Letters

All letters

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

LQDA $3.1B
Trade Ideas Flow 4 clicks

Mereo Biopharma

Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.

MREO $49M
Raging Bull Investments

Revisiting An Old Idea

Instil Bio leased its 128,000-square-foot Tarzana life-sciences building to AstraZeneca for 15 years at $7.52 million annual rent,…

TIL $40M
Raging Bull Investments

JBG Smith

JBG Smith trades at an estimated 40% discount to NAV, backed by National Landing multifamily assets, Amazon HQ demand and $1.3 billion of…

JBGS $813M
Raging Bull Investments

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 235

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.